The treatment effect of rivaroxaban on clot characteristics in patients who present acutely with first time deep vein thrombosis by Vanessa, Evans et al.
1 
 
Title: The treatment effect of rivaroxaban on clot characteristics in patients who present 
acutely with first time Deep Vein Thrombosis 
Running header: Validation of a biomarker of clot structure in anticoagulation treatment 
 
Authors: V J Evans1,2, M Lawrence1,2, J Whitley1,2, C Johns3, S Pillai1,2, K Hawkins2, K Power3, 
K Morris4, R Williams2, P A Evans1,2 
 
Institution List: 1 Welsh Centre for Emergency Medicine Research, Morriston Hospital, 
Swansea Bay University Health Board, Swansea, UK; 2 Swansea University, Swansea, UK; 3  
Swansea Bay University Health Board, Swansea, UK; 4 Cardiff Metropolitan University, 
Cardiff, UK. 
 
Corresponding Author: Professor Phillip Adrian Evans, Welsh Centre for Emergency 
Medicine Research, Morriston Hospital, Swansea Bay University Health Board, Swansea, 
UK, SA6 6NL, Tel: 01792 703718, email: phillip.evans2@wales.nhs.uk 
Word Count: 4724 
Number of Figures: 2 
Number of Tables: 5 
 
Keywords  
rivaroxaban, coagulation inhibitors, venous thrombosis, clot structure, biomarkers 
2 
 
Abstract (Max 250 words) 
BACKGROUND: The acute vascular disease deep vein thrombosis (DVT) requires oral 
anticoagulants to prevent progression. Monitoring therapeutic efficacy of direct oral 
anticoagulants (DOAC), including rivaroxaban, is problematic as no reliable test is available. 
Advances in rheometry have led to the development of a functional coagulation biomarker 
using Gel Point (GP) analysis which assesses clot structure formation. The biomarker 
measures incipient clot formation time (TGP) and quantifies fibrin clot structure in terms of 
fractal dimension (df). 
OBJECTIVE: This study aimed to investigate clot structure formation in first time DVT and the 
effect of rivaroxaban treatment. 
METHODS: This prospective observational cohort study measured the GP and standard 
laboratory markers at three sample points: pre-treatment and at 20 and 60 days following 
15mg BD and 20mg OD rivaroxaban respectively.  
RESULTS: Forty DVT patients (mean age 64 years [SD±14.8]; 23 males, 17 female) were 
recruited. The results show that DVT vs non-DVT patients did not have a significantly different 
GP profile (df: 1.72±0.06 vs 1.70±0.06 and TGP: 267±68sec vs 262±73sec) with both within the 
defined healthy index. In addition, rivaroxaban therapy increased TGP to 392s (±135s) after 20 
days, and subsequently increased to 395s (±194s) at 60 days but did not significantly increase 
df (from 1.69±0.05 to 1.71±0.06).  
CONCLUSIONS: The results indicate in this cohort of DVT patients there was no underlying 
hypercoagulable effect as determined by gel point analysis. Furthermore, the anticoagulant 
effect of rivaroxaban prolonged clotting, suggesting a protective effect against clot formation, 




What does this paper add? 
• First time DVTs do not demonstrate abnormal clot characteristics  
• Gel point analysis quantifies the effect of rivaroxaban and alteration in dosage 






Deep vein thrombosis (DVT) is a serious and potentially life-threatening condition that affects 
up to 1 million people annually in Europe.[1,2] Prompt diagnosis and effective management 
of DVT are the key goals in improving outcome in these patients.[3-5] Risk of recurrence 
remains a problematic issue particularly in unprovoked DVT, with a risk of recurrence 
approximately 10% in the first year post event, raising to 30% in 5 years.[6-7] Current 
guidelines recommend the use of oral anticoagulants as first line therapies in the 
management of DVT.[8,9] The use of anticoagulation prevents the ongoing development of 
the thromboembolism and reduces the risk of complications over the acute phase of the 
disease.[9] Increasingly, the use of Direct Oral Anticoagulants (DOACs), such as rivaroxaban 
and apixaban, are replacing longer established anticoagulants such as warfarin. The 
advantages of DOACs over warfarin include fixed dosing regimens and reduced clinical 
monitoring.[10] This has resulted in DOAC prescribing in England, as a proportion of total 
anticoagulant prescribing, increasing from 9% in 2014 to 74% in 2019.[11] One of the 
challenges faced by clinicians in the management of unprovoked DVT, is in deciding which 
patients benefit from time limited anticoagulation, and which require longer term 
anticoagulation.[12] DVT patients are a heterogeneous group, complicated by multiple risk 
factors for bleeding or thromboembolism, including age, renal function, body weight, frailty, 
and the presence of comorbid disease which all may influence the response to DOACs and 
the subsequent safety of these agents.[13,14]  This promotes a difficult clinical question in 




Despite the clear advantages of DOACs over the older oral anticoagulants, bleeding remains 
a concern for those requiring long term anticoagulation.[15,16] Furthermore, there is 
currently no readily available bedside test that accurately measures the therapeutic effect of 
DOACs. Ultraperformance liquid chromatography–tandem mass spectrometry (UPLC-
MS/MS) is the standard for accurate quantification of serum DOAC levels but is limited by 
slow turnaround times and methodologically demanding processes, making it clinically 
impractical.[16] Drug specific chromogenic anti-Xa assays are recommended as a means of 
quantifying drug levels of the direct factor Xa inhibitors (apixaban, edoxaban, and 
rivaroxaban), but are limited by poor reliability, long turnaround time and relatively high 
cost.[10] There are currently several tools to predict VTE recurrence (e.g.ERDOO2, Vienna, 
Dash) and bleeding risk (e.g. VTE bleed, HASBLED), however, most of these tools have 
limitations or have not been validated.[17,18] As a result, there is a growing need for the 
development of other effective tools and techniques to better assess the risk benefit/ratio for 
oral anticoagulation in DVT and evaluate its management. 
 
Current research has identified a prothrombotic plasma fibrin clot phenotype associated with 
DVT and PE.[19-22] This fibrin clot phenotype shows a relationship between risk of recurrence 
and altered clot microstructural properties measured by clot lysis time (CLT) and clot structure 
permeability. Reduced clot structure permeability and prolonged CLT are predictive of DVT 
recurrence following withdrawal of anticoagulation. It has also been previously shown that 
VTE patients taking rivaroxaban have improved blood viscoelastic properties compared to 
healthy controls, which are known to be some of the most sensitive measures of clot 
formation.[23-26] Advanced viscoelastic techniques can also be used to link changes in 
viscoelasticity to features of clot structure formation.[27] This technique uses Gel Point (GP) 
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analysis and has been investigated and validated in a number of disease states.[28-30] The 
GP biomarker can provide a point of care, rapid assessment of viscoelastic and microstructural 
properties in coagulating blood. Previous studies have shown that GP analysis is a potential 
indicator of anticoagulation effectiveness and increased risk of VTE recurrence in patients 
with a first time DVT.[27,31] 
 
We had previously shown that GP analysis was a significant marker of clot formation in the 
treatment of VTE. In anticoagulation we hypothesised that the GP analysis will also be capable 
of identifying the forgoing effects of rivaroxaban in first time DVT patients. To investigate this 
hypothesis, the present study aimed to determine changes in clot structure in a cohort of 
patients with suspected first time DVT compared to non-DVT patients. We also aimed to 




Materials and Methods 
Study design and population group 
This study complies with the declaration of Helsinki and ethical favourable opinion was gained 
from Hampstead Research Ethics Committee (MREC no: 14/LO/1231). Adults≥18 years 
attending the Acute GP Unit (AGPU) for investigation of possible DVT were screened for 
eligibility. Informed written consent was obtained from all recruited participants and 
confirmation of ongoing consent was reiterated at each sample point. Exclusion criteria 
included: 1) Previous DVT or PE; 2) Dual antiplatelets or long-term non-steroidal anti-
inflammatory drugs; 3) Current oral anticoagulation therapy; 4) pregnancy; 5) active cancer; 
6) any systemic disease known to affect the coagulation system; 7) intravenous drug users; 8) 
known to have HIV or hepatitis; 9) liver disease; 10) severe renal impairment – stage 4-5 
chronic kidney disease; 11) known hereditary clotting disorders; 12) previous family history 
of VTE. 
 
Following informed consent, a blood sample was taken at the same time as standard 
investigational blood tests. The patients under the care of the AGPU followed the 
investigational protocol of the hospital including completion of the Wells Score and 
subsequent D-dimer and/or Doppler ultrasound scan as indicated. For patients who did not 
have a DVT, they entered the non-DVT group for analysis. Patients with a confirmed DVT were 
started on a treatment and regime appropriate for their diagnosis i.e. 3 months for provoked 
and 6 months for unprovoked DVT. Patients who commenced on the DOAC rivaroxaban were 
followed up within 21 days to provide the change of dose, and again approximately 1 month 





A 7ml baseline sample (Sample A) was collected from all participants prior to any treatment 
at the initial assessment for possible DVT following fully informed consent and meeting of 
inclusion and exclusion criteria. Participants with a confirmed DVT by doppler ultrasound who 
commenced rivaroxaban treatment had a 7ml blood sample taken at approximately 20 days 
(Sample B) whilst on the 15mg BD dose of rivaroxaban. The dose change of rivaroxaban to 
20mg OD occurs post day 21 of treatment. The final sample of 7ml (Sample C) was taken 60-
90 days from the initial commencement of treatment. Blood testing as part of the patient’s 
standard care was taken at the same time to minimise venepuncture for the patient. Standard 
testing included full blood count (FBC), coagulation testing, urea and electrolytes. The full 
range of testing was performed on all patients at each sample point. The rate of attrition of 
the study was very low with a 100% follow up at sample B and 95% in sample C. Each 7ml 
sample underwent haemorheological testing (6.6ml) and in addition 21µl was used to obtain 
SEM images of whole blood mature clots formed ex vivo. 
 
GP Analysis 
In this study a 6.6 ml aliquot of whole unadulterated venous blood was loaded into a double-
gap concentric cylinder measuring geometry of a TA Instruments AR-G2 (TA Instruments, New 
Castle, DE, USA) controlled-stress rheometer (at 37oC ± 0.1oC) in a near patient setting and 
tested immediately to obtain the GP, which identifies the transition of the blood from a visco-
elastic liquid to a visco-elastic solid [27]. Figure 1 shows the quantification of the GP, where 
blood is loaded between two surfaces, to which small amplitude oscillatory stress 
measurements are taken (Figure 1 A). These measurements are used to measure the phase 
angle of the material. The phase angle measures viscoelasticity and has a range from zero to 
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ninety degrees. Phase angle measures whether the material deforms elastically like a solid 
(low phase angle result) or flows like a liquid (high phase angle result). To obtain the GP 
measurement the phase angle is measured over time as the blood clots (Figure 1 B). Four 
different frequencies are used (2Hz, 1.2Hz, 0.6Hz and 0.2Hz) to measure the changes in phase 
angle. The point where phase angle becomes frequency independent (crossover of the 4 
frequencies) is the GP and is deemed the point where the blood first becomes a sample 
spanning haematological stable clot. It has been previously established that the phase angle 
at the GP is synonymous with the fibrin structure of the clot and can be quantified using fractal 
dimension, df.[26,27] Therefore, GP results provide several useful measures of clotting (i) the 
time taken to reach the GP (the incipient clot formation time), TGP; (ii) the shear elastic 
modulus at the GP, G’GP, which is a measure of the elasticity of the incipient clot; and (iii) the 
fractal dimension of the clot, df, which is a quantification of the clot’s fibrin structure. The GP 
technique has been previously validated for use with blood in several studies [2,5,6]. 
 
Scanning electron microscopy (SEM) 
Scanning electron microscopy was performed on coagulated blood for a sample of the DVT 
patients receiving rivaroxaban. Samples at baseline, 21 days and 3 months were analysed to 
investigate the effect of anticoagulation on clot structure formation. Clots were washed with 
ca-codylate buffer and fixed with glutaraldehyde. Point-critical dehydration with ethanol (30-
100%) and hexamethyldisiazane fixed the samples for imaging. The sample underwent 







Each participant had a full blood count measured at all sample points. Blood was collected in 
4ml full-draw dipotassium EDTA Vacuettes (Becton Dickinson, Plymouth, UK Ref: 367839). 
Within 2 hours of sample collection the blood was analysed using the Sysmex XE 2100 (Sysmex 
UK, Milton Keynes, UK) automated haematology analyser. Each participant also had routine 
coagulation studies at all sample points. 2.7ml of blood was drawn into a citrated silicone 
glass Vacutainer (0.109 M) (Becton Dickinson, Plymouth, UK Ref: 367691). Prothrombin Time 
(PT), activated partial thromboplastin time (APTT) and Clauss fibrinogen were measured using 
a Sysmex CA1500 analyser. Fibrinogen calibration was verified against the 2nd International 
Fibrinogen Standard Version 4 (NIBSC code 96/612). All reagents were obtained from 
Siemens, (Frimley, UK). All testing was performed within 2 hours of sample collection. D-dimer 
analysis was carried out in presenting patients with possible DVT. D-dimer analysis was carried 
out using latex immunoturbidimetric assay Hemosil HS d-dimer (Instrumentation Laboratory, 
Warrington, UK). The d-dimer assay was performed on an ACL TOP 500 (Instrumentation 
Laboratory, Warrington, UK). Urea and electrolytes were measured in all participants at all 





Descriptive analyses were performed to establish baseline characteristics. Results are 
reported as mean (±SD) unless otherwise stated. The normality was assessed using normal 
probability plots and Shapiro–Wilk test. Two sample t-test and Wilcoxon signed-rank were 
used to compare differences between two sampling points and one-way ANOVA with 
11 
 
Bonferroni analysis was used to compare differences across all sampling points. Spearman's 
correlation analysis was undertaken to explore any associations between various tests as 
defined from the start of symptoms to the time blood was taken. Differences were assumed 
to be significant at p<0.05 and actual probability values are quoted when deemed significant. 
IBM Statistical Package for Social Sciences (SPSS) for Windows, version 22.0 (Armonk, NY: IBM 
Corp.) and Minitab version 16 software (Havertown, PA) were used to perform the analysis. 
Analysis of covariance using a general linear model was also used to model the effect on TGP 







A total of 217 were included in the study, 40 with confirmed DVT and 177 tested negative for 
DVT. Demographic information about the DVT and non-DVT groups can be found in Table 1. 
The age, BMI, social factors and co-morbidities were all comparable across the groups. There 
were a significantly higher number of females investigated for DVT than males, although more 
males were confirmed to have a DVT. Provoking factors of DVT were recorded in 9 of the 
confirmed DVT group including 3 relating to travel, 5 orthopaedic lower limb surgeries and 1 
lower limb plaster cast. Any missing data was excluded from the analysis. For comparisons 
between DVT and non DVT only baseline samples were used. For DVT patients only those who 
completed all three samples were included in the analysis.  
 
GP markers 
Results of the GP markers can be observed in Table 2 and 3. Both TGP and df were higher in 
the confirmed DVT group vs non-DVT group, however not significantly. Sampling at the 3 time 
points (baseline, rivaroxaban 15mg BD, and rivaroxaban 20mg OD) showed significant 
prolongation of the TGP and a non-significant reduction in df. Baseline measurement of TGP of 
267.0 ± 63.3 in the DVT group was significantly increased with treatment raising significantly 
to 392.3 ± 135.7, this prolongation of TGP at 395.5 ±194.2 is maintained at the final sample 
point with the reduced dose to 20mg OD. 
 
Standard markers 
Results of the standard markers can be observed in Table 2 and 3. On diagnosis markers of 
inflammation: white cell count, neutrophils and monocytes were significantly elevated in the 
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confirmed DVT group. Analysis of the DVT group indicate that the fibrinogen concentration, 
white cell count, neutrophils and monocytes were all significantly raised compared to the non 
DVT group. The standard laboratory markers over the 3 time points in the DVT group indicated 
significant reduction of the white cell count and fibrinogen concentration at time points B and 
C compared to baseline.  
 
Scanning Electron Microscopy  
The images in Figure 2 show the fibrin network of an anticoagulated sample receiving the 
maximum dose of 15mg BD with a df of 1.69 alongside a non-anticoagulated sample with a df 
of 1.73. Comparison between the two images can be objectively made regarding fibre width, 
branching and openness of fibres. The sample with rivaroxaban appears to have thinner fibres 
with increased branching but with increased porosity.  
 
 
DVT group – with confirmed PE 
Within the DVT group, 3 individuals received investigation into pulmonary embolism, all were 
confirmed as positive. Non-parametric analysis comparing these 3 PE to the rest of the group 
was non-significant although as further investigations to rule out or diagnose PE were not 




Table 1: Table of demographics and comorbidities for confirmed Deep Vein Thrombosis and 
non-Deep Vein Thrombosis patient groups. Results include mean ± standard deviation, or 
number (percentage of the representative group). Significance differences determined using 
independent t-tests. * indicates significance. (BMI - Body mass index, AF - Atrial fibrillation)  
 
 DVT Non-DVT Significance 
value 
N 40 177  
Sex M/F 24/16 66/111 0.008* 
Age (years ± SD) 64 ± 14.9 61 ± 16.6 0.359  
BMI (± SD) 29.3 ± 5.5 31.3 ± 7.0 0.1114 
Current smoker 10 (25%) 32 (18%) 0.319 
Current alcohol use 35 (87.5%) 140 (79%) 0.226 
Comorbidities  
Hypertension 14 (35%) 77 (43.5%) 0.314 
Diabetes 4 (10%) 24 (13.6%) 0.606 
Hypercholesterolaemia 8 (20%) 36 (20.3%) 0.949 





Table 2: Viscoelastic, haematological and coagulation biomarkers for Deep Vein Thrombosis 
and non-Deep Vein Thrombosis groups at presentation of symptoms. Viscoelastic markers 
(df – fractal dimension, TGP(s) – Time to gel point in seconds). Coagulation markers (PT – 
prothrombin time, APTT - activated partial thromboplastin time) Values reported as mean ± 
Standard Deviation. Significance differences determined using independent t-tests. * 
indicates significance. 
 DVT Non-DVT Significance value 
df 1.717 ± 0.059 1.705 ± 0.059  0.290 
TGP(s) 267 ± 68 262 ± 73 0.755 
Platelets (x109/L) 241 ±73 259 ± 66 0.121 
Haematocrit (l/l) 0.429 ± 0.048 0.423 ± 0.046 0.474 
White Blood 
Cells(x109/L)  
9.2 ± 2.8 7.7 ± 2.1 0.001* 
Neutrophils(x109/L) 6.3 ± 2.4 4.9 ± 1.8 0.001* 
PT (s) 10.8 ± 0.6 10.6 ± 0.6 0.010* 
APTT (s) 24.3 ± 2.3 24.6 ± 1.9 0.495 





Table 3: Viscoelastic, haematological and coagulation biomarkers for DVT group at baseline 
and during treatment. Viscoelastic markers (df – fractal dimension, TGP(s) – Time to gel point 
in seconds). Coagulation markers (PT – prothrombin time, APTT - activated partial 
thromboplastin time). Values reported as mean ± Standard Deviation. Significance between 




15mg BD dose 
Rivaroxaban 
20mg OD dose 
Significance 
value 
df 1.72 ± 0.059 1.69 ± 0.051 1.71 ± 0.06 0.136 
TGP (s) 267.1 ± 68.0§ 392.3 ± 135.7 395.5 ± 194.2 <0.001* 
Platelets 
(x109/L) 
241 ±73 261 ± 93 255 ± 70 0.289 
Haematocrit 
(l/l) 
0.429 ± 0.048 0.436 ± 0.055 0.441 ± 0.053 0.335 
White Blood 
Cells (x109/L) 
9.2 ± 2.8§ 7.8 ± 2.3 7.6 ± 2.1 <0.001* 
PT (s) 10.8 ± 0.6§ 13.6 ± 1.7 12.7 ± 1.4 <0.001* 
APTT (s) 24.3 ± 2.3§ 35.3 ± 5.3 33.6 ± 6.4 <0.001* 
Fibrinogen (g/l) 4.0 ± 0.9¥ 3.4 ± 0.7 3.1 ± 0.6 <0.001* 
 
¥Significantly different from the Rivaroxaban 20mg OD dose only after Bonferroni correction. 





The role of gender in DVT patients 
A significantly greater proportion of males in the DVT group as compared to the non-DVT was 
observed (Table 1). We explored for gender differences in the rheological markers in the DVT 
group and the analysis is presented in Table 4. TGP was found to be significantly increased 
after treatment with rivaroxaban and that this was the case regardless of gender. 
Furthermore, the relationship between df and TGP in both the females and males showed a 
significant negative correlation between df and TGP in females (Pearson correlation coefficient 
r= -0.401 p<0.05) but this relationship was not observed in males.  At all the timepoints 
analysed females had a significantly reduced df as compared with males (baseline: 1.69±0.06 
vs 1.73±0.05 (p=0.03) 15mg BD dose: 1.67±0.05 vs 1.70±0.05, p=0.04) 20mg OD dose: 
1.68±0.05 vs 1.73±0.06 ( p=0.01)). These results indicate that males have a significantly higher 
df than females throughout and that this is associated with a shortening of the TGP. 
Furthermore, although rivaroxaban therapy in males reduces df and shortens TGP at the 
second time point (15mg BD dose), at the third time point (20mg OD dose) df returns to the 
baseline value suggesting that rivaroxaban therapy is unable to regulate clot structure and 





 Baseline Rivaroxaban 
15mg BD dose 
Rivaroxaban 




Male 1.73 ± 0.05§ 1.70 ± 0.05 1.73 ± 0.06§ 0.114 
Female 1.69 ± 0.06§ 1.67 ± 0.05 1.68 ± 0.05§ 0.587 
TGP(s) 
Male 284.3 ± 72.5 388.3 ± 110.8 330.8 ± 108.3§ 0.003* 
Female 241.6 ± 54.4 399.1 ± 173.7 494.9 ± 256.9§ 0.002* 
 
Table 4: df and TGP in males and females with DVT. DVT group at baseline and on treatment 
for males (n=24) and females (n=16). Values reported as mean ± Standard Deviation. 
Significance values between male and females was assessed using a two-way ANOVA (§ 




Follow up data was collected at 3.5 years for each of the 40 confirmed DVT patients. Eleven 
recurrences of DVT were reported after 3.5 years. All of the recurrent DVT patients had an 
unprovoked original DVT. The location of the recurrent DVT occurred in the same leg in eight 
of the incidences, with four of these in the same region and four in a different location of the 
same leg. Given the significant role of both df and TGP we observed in subjects with DVT, we 
specifically investigated if significant differences existed between these biomarkers in 
subjects with a recurrence of DVT at each time treatment point within 3.5 years of admission. 
The results are presented in Table 5. At baseline df and TGP was significantly higher in the 
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recurrent group as compared to the non-recurrent group. The results in dose regimes of 
rivaroxaban in the recurrent and non-recurrent groups shows a prolongation of TGP and 
reduction in df.  
 
 Baseline Rivaroxaban 15mg BD dose Rivaroxaban 20mg OD dose 
df 
Non-recurrent 1.71 ± 0.06§ 1.70 ± 0.05 1.69 ± 0.06 
Recurrent 1.75 ± 0.06§ 1.69 ± 0.05 1.72 ± 0.05 
TGP(s) 
Non-recurrent 281.5 ± 69.84* 406.4 ± 139.54 384.6 ± 154.29 
Recurrent 227.7 ± 38.94* 354.4 ± 108.40 335.5 ± 72.80 
 
Table 5: df and TGP in subjects with recurrent and non-recurrent DVT. DVT group at baseline 
and on treatment for recurrence (n=11) and non-recurrence (n=29). Values reported as mean 
± Standard Deviation. Significance values between recurrence (n=11) and non-recurrence at 
each treatment point was assessed using a two-sample t-test (§indicates significance p<0.01 





Figure 1: Diagrammatic representation of the GP experiment: Figure 1A represents blood 
contained between two testing surfaces where small amplitude oscillatory stress 
measurements are performed and the resultant strain waveform is recorded. The differences 
in phase between the stress and strain waveforms are recorded as the phase angle. Figure 1B 
represents a typical gel point experiment result showing the change in phase angle for 4 
different testing frequencies with respect to time. The GP is located where the 4 frequencies 
crossover. The GP defines the transition of the blood from a liquid to a solid and is the first 
point where a sample spanning haematological stable clot is formed. The TGP (Time to GP) 
assesses the kinetic pathways during the liquid phase of clot formation and is a measure of 
clotting time. The phase angle at the GP is synonymous with clot structure and can be 
converted to fractal dimension. Where a high phase angle equals a low df value which 
indicates a loose/open fibrin clot structure and a low phase angle equals a high df value 








Figure 2: Scanning Electron Microscopy imaging of the fibrin network of an anticoagulated 
sample receiving the maximum dose of 15mg BD with a df of 1.69 alongside a non-






In this study we assessed the effect of rivaroxaban on viscoelastic and microstructural 
properties of the blood using GP analysis in first time DVT patients. The results for df in the 
DVT positive group show a trend to the formation of looser more open clot structure, 
especially during the maximum dose (15mg BD) given at the second time point. The  changes 
in df would appear to be small but we have previously reported that these changes correlate 
with large changes in clot mass observed through SEM imaging.[30] Rivaroxaban increases 
the permeability and degradability to lysis of the fibrin clot, a feature consistent with a 
reduced df.[39] However, our initial analysis shows the df returns to its near original level on 
the reduced dose (20mg OD). [21] In contrast, the effect of rivaroxaban on TGP shows a 
significant prolongation at both dose regimes.  
 
Interestingly, further analysis demonstrated that gender was a significant predictor of 
response to rivaroxaban therapy in terms of df and TGP. We show that females at baseline had 
a significantly lower df and end up with a longer TGP, it is possible that rivaroxaban has a 
greater effect on females over males. The fact that males are showing significantly higher 
values of df suggests that males have a different clotting profile resulting in a different clot 
morphology than females. It has been reported that  males in the wider population are at 
increased risk of DVT and thromboembolism.[40] A previous study in VTE patients fully 
anticoagulated with warfarin demonstrated that those patients who were found to have a 
higher df despite anticoagulation had a higher incidence of thromboembolic recurrence.[31]  
In the present study we show that rivaroxaban reduces df and prolongs TGP in males at the 
15mg BD dose, however, these effects are almost completely reversed at the 20mg OD dose, 
returning the GP clotting characteristics back to the baseline results. In comparison, females 
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at both dosing regimens show a non-significant reduction in df and a significantly prolonged 
TGP, with the largest change in TGP seen at the 20mg OD dose. This suggests that rivaroxaban 
administration in DVT is potentially complex, with the 20mg OD dose seemingly more 
effective in females than males. This work provides evidence for the rationale of a 
personalised medicine approach where perhaps differences in gender (and other potential 
cofactors) should be considered when prescribing oral anticoagulants, as the effect of these 
agents may not be universal across all groups. This may be especially of clinical importance 
given the established higher risk of recurrent VTE seen in males compared to females.[40] 
 
The significant prolongation of TGP may be part of the success of rivaroxaban treatment as a 
long term VTE prophylaxis, especially with consideration of stasis as an initiator in this disease. 
Fibrin fibres densities and thicknesses obtained in previous studies suggested that 
rivaroxaban resulted in the formation of ‘looser’, thicker fibres but this was not confirmed in 
the present study.[21] This study suggests that the effectiveness of the rivaroxaban is to 
provide a protective effect from slowing any clot formation whilst also maintaining a normal 
clot microstructural template (maintain a df value within the normal range). This may also 
provide a rationale for why rivaroxaban is shown to have all the benefits of old oral 
anticoagulation (such as warfarin) but at a reduced bleeding risk.[17] Where clotting whilst 
on rivaroxaban may take longer to form there is still the ability to form a good quality clot. 
This is not necessarily true with other anticoagulants which have been shown to dramatically 
reduce clot microstructural properties.[27,31]  
 
The viscoelastic and microstructural characteristics of these DVT patients suggests that there 
is no systemic hypercoagulable effect (Table 2), despite significant increases observed in 
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fibrinogen concentration and white blood cell. Furthermore, TGP and df for both the DVT and 
non-DVT groups fall within the previously described normal healthy range.[27] The increase 
in fibrinogen concentration and white blood cells would be expected in thrombosis of the 
lower limbs, this is primarily a function of inflammation due to the thrombus formation.[32] 
However, in the non-DVT group the values were all within or marginally outside the normal 
range (fibrinogen concentration  1.5-4.5 g/L,  WBC 4 and 11x109/L, neutrophils 2.0-7.5x109) 
[33] potentially supporting our finding of no significant difference in the markers of 
coagulation between the two studies.  We would propose that any hypercoagulability in first 
time DVT is a localised effect close to the site of injury. Inflammation is considered causative 
of and reactive to thrombosis as thrombin stimulates inflammatory mediators (e.g. 
interleukin(IL-6,  IL-8) that activate the coagulation cascade.[34,35]  Localised coagulation, in 
response to endothelial injury, is also an established concept, with fibrinolysis, via the primary 
fibrinolysin plasmin, acting as a natural control mechanism to prevent systemic thrombotic 
syndromes.[36] Importantly, we also report that the baseline df and TGP were both 
significantly higher and lower respectively, in the subjects with a recurrent DVT within 18 
months, suggestive of a more rigid denser clot in this group. 
Limitations of this study include the small sample size when considering subgroup analysis, in 
particular due to the small numbers it was not possible to analyse for gender in the recurrent 
and non-recurrent groups. 
 
This study is the first to investigate first time DVT patients using GP analysis over the 
commencement of their oral anticoagulation treatment with rivaroxaban. In the study we 
show that for these patients first time DVT does not induce a systemic hypercoagulable state. 
In this study, we also have shown that the GP analysis is able to quantify the effects of 
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rivaroxaban on blood coagulation in terms of viscoelasticity and clot structure. Where 
rivaroxaban significantly prolongs clotting time (TGP) but does not significantly alter clot 
microstructural properties. This would indicate that rivaroxaban provides the protection of 
oral anticoagulants whilst maintaining the ability of the blood to form stable healthy clots. 
Further work now needs to be carried out to investigate the effectiveness of GP analysis as a 
predictor of outcome or recurrence in DVT and comparison for different oral anticoagulants 
prescribed for the treatment of DVT with testing of anti-factor Xa levels or LMWH standards.  
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